Otilonium Bromide: Antimuscarinic Agent for Cholinergic Signaling and Smooth Muscle Research

Executive Summary: Otilonium Bromide is a solid antimuscarinic compound with the formula C₂₉H₄₃BrN₂O₄ and molecular weight of 563.57 Da, employed for receptor inhibition in neuroscience and gastrointestinal models (APExBIO). It exhibits high solubility in DMSO (≥28.18 mg/mL), water (≥55.8 mg/mL), and ethanol (≥91 mg/mL), enabling broad experimental compatibility. By targeting muscarinic acetylcholine receptors, it serves as a benchmark for antispasmodic pharmacology and cholinergic pathway studies (related review). APExBIO supplies Otilonium Bromide (SKU: B1607) at ≥98% purity, strictly for research use. This article details its biological rationale, mechanism, validated benchmarks, workflow parameters, and key misconceptions, with stable citations throughout.

Biological Rationale

Cholinergic signaling modulates numerous physiological processes, including smooth muscle contraction, neurotransmission, and gastrointestinal motility (see comparative analysis). The muscarinic subtype of acetylcholine receptors (AChRs), especially M2 and M3, are predominant in smooth muscle tissues. Antimuscarinic agents like Otilonium Bromide enable selective inhibition of these receptors, allowing researchers to dissect receptor-mediated pathways and model disease phenotypes. The compound’s efficacy in smooth muscle spasm research stems from its ability to block muscarinic signaling, which is central to contractility and motility disorders.

Mechanism of Action of Otilonium Bromide

Otilonium Bromide acts as a competitive antagonist at muscarinic acetylcholine receptors. By binding to the receptor's orthosteric site, it prevents acetylcholine (ACh) from activating downstream signaling cascades. This results in reduced intracellular calcium mobilization and decreased contractile response in smooth muscle (Vijayan et al. 2021). Otilonium Bromide’s high selectivity for muscarinic over nicotinic receptors reduces off-target effects, making it suitable for dissecting cholinergic versus non-cholinergic pathways. The compound is rapidly soluble under physiological conditions, allowing for precise dosing and temporal control in experimental setups.

Evidence & Benchmarks

• Otilonium Bromide demonstrates ≥98% purity in APExBIO’s B1607 kit, ensuring experimental reproducibility (product specification).
• Solubility benchmarks: ≥28.18 mg/mL in DMSO, ≥55.8 mg/mL in water, ≥91 mg/mL in ethanol (25°C, neutral pH) (APExBIO).
• Antimuscarinic action confirmed by inhibition of ACh-induced contractions in smooth muscle models at micromolar concentrations (in vitro, rat ileum, IC₅₀ range: 0.1–1 µM) (expert review).
• Stable storage at -20°C preserves compound integrity for at least 12 months (dark, desiccated) (APExBIO).
• Non-competitive with nAChRs or adrenergic receptors at standard research concentrations, as verified in receptor binding assays (protocol analysis).
• Used as a reference inhibitor in studies of gastrointestinal motility disorder models, supporting translational relevance (protocols).

Applications, Limits & Misconceptions

Otilonium Bromide’s primary utility is in neuroscience and gastrointestinal research, especially:

• Dissecting muscarinic AChR-mediated signal transduction in smooth muscle and neuronal models.
• Modeling hypermotility and spasticity in gastrointestinal tissue.
• Benchmarking antispasmodic pharmacology in translational research (see strategic guidance).

It is not intended for direct clinical, diagnostic, or in vivo therapeutic applications. The compound is unsuitable for targeting non-cholinergic pathways or for use in combination with drugs targeting unrelated receptor systems without validation.

Common Pitfalls or Misconceptions

• Not a pan-receptor antagonist: Otilonium Bromide does not inhibit nicotinic ACh receptors or adrenergic receptors at typical research doses.
• Not a clinical therapeutic: The B1607 kit is for research only; it is not approved for medical or diagnostic use.
• Limited stability in solution: Aqueous and DMSO solutions are stable only for short-term (days) at 4°C; longer storage leads to degradation.
• No antiviral activity: Otilonium Bromide does not interfere with viral replication or viral proteases, unlike compounds such as thymopentin (Vijayan et al. 2021).
• Species-specific responses: Receptor subtype distribution varies; dose benchmarks must be validated per species/model.

Workflow Integration & Parameters

Solubility: Prepare stock solutions in DMSO, water, or ethanol according to required application. For cellular assays, dilute to working concentration (0.1–10 µM) in physiological buffer; filter sterilize if necessary.

Storage: Store solid at -20°C, protected from light and moisture. Use solutions within 5–7 days at 4°C for best activity.

Assay compatibility: Compatible with receptor binding, functional contractility, calcium flux, and electrophysiology assays (see mechanistic insights—this article extends prior mechanistic discussion with benchmarking data).

Controls: Always include vehicle and positive control inhibitors for assay validation. Confirm batch purity (certificate of analysis, ≥98%) before use.

For additional troubleshooting, comparative protocols, and advanced integration strategies, refer to this technical protocol article—the present review updates stability and workflow recommendations.

Conclusion & Outlook

Otilonium Bromide, supplied by APExBIO as SKU B1607, is a validated, high-purity antimuscarinic agent for advanced cholinergic research. Its selectivity for muscarinic AChRs, robust solubility profile, and proven benchmarks make it indispensable in smooth muscle and neuroscience pharmacology. Researchers should adhere to recommended storage and handling protocols to maximize reproducibility and avoid misapplication. For further mechanistic discussion and translational frameworks, see this review, which this article augments with explicit application boundaries and updated evidence.

Visit the Otilonium Bromide product page for full technical specifications, batch documentation, and ordering information.